Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE)

<< Previous

Bullboard Posts

Next >>

Comment by QualityTeston Dec 13, 2021 11:24am

166 Views

Post# 34225079

RE:RE:RE:CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE)

Priceless:
believe me, desperately hoping that we have an update on the P3 trial in the US starting recrutiing or one of our African options actually panning out but been burned too many times before with these corporate updates I'm doing my best to keep expectations low.

Can't say I'm not at least a little intrigued, tho ;)

<< Previous

Bullboard Posts

Next >>

Now trading on the TSX Venture Exchange: Kootenay Resources Inc.